Michelle Peters Wellington announced Thursday that she has joined Vistagen Therapeutics as VP of communications. MM+M’s third ...

This novel delivery method, applied to the inside of the cheek, offers a streamlined two-hour in-clinic treatment. Atai plans to begin a Phase 2 study by the end of 2024 to evaluate VLS-01's safety, ...

We have observed statistically significant efficacy and favorable safety data in each of our lead intranasal pherine development programs, for fasedienol in a Phase 3 trial for the acute treatment of ...

The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); ...

If you don’t have a family history of anxiety disorders, you still might be at risk. With our LiveWell app and website, you can manage health and wellness for yourself and for everyone who counts on ...

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...

Atai Life Sciences N.V. ( (ATAI) ) has released its Q3 earnings. Here is a breakdown of the information Atai Life Sciences N.V. presented to ...

The company is set to begin Phase 2 trials for VLS-01 in treatment-resistant depression and EMP-01 for social anxiety disorder by the end of 2024. With FDA clearance for VLS-01 and a strategic ...

They also mentioned that IGD never comes as a single disorder, it co-occurs with other mental health issues such as ...

Though it’s the most common skin condition in the United States, determining the best acne treatment for your skin is still challenging. Acne treatments include prescription medications ...

The clinical-stage biopharmaceutical company said it has enough cash to reach the milestones it laid out for 2025.